MENLO PARK, Calif.--(BUSINESS WIRE)--June 7, 2006--Depomed, Inc. (Nasdaq:DEPO - News) announced today that the results of a second Phase 3 clinical trial with Glumetza(TM) (metformin hydrochloride extended-release tablets) for the treatment of Type 2 diabetes mellitus were published in the June 2006 issue of Diabetes: A Journal of the American Diabetes Association 2006; 55 (suppl 1; 66th Scientific Sessions Abstract Book): 1999-PO. The data demonstrated that adding Glumetza, an FDA-approved, once-daily version of metformin, to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone.
